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goals include achieving modiﬁed New York Heart Association functional class I or II, 6-min walk distance >380 m,
normalization of right ventricular size and function on echocardiograph, a decreasing or normalization of B-type
natriuretic peptide (BNP), and hemodynamics with right atrial pressure <8 mm Hg and cardiac index >2.5 mg/kg/
min2. However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that
the “bar” needs to be set higher, with more robust and clearer delineations aimed at parameters that correlate with
long-term outcome; namely, exercise capacity and right heart function. Speciﬁcally, tests that accurately and
noninvasively determine right ventricular function, such as cardiac magnetic resonance imaging and BNP/N-terminal
pro–B-type natriuretic peptide, are emerging as promising indicators to serve as baseline predictors and treatment
targets. Furthermore, studies focusing on outcomes have shown that no single test can reliably serve as a long-term
prognostic marker and that composite treatment goals are more predictive of long-term outcome. It has been
proposed that treatment goals be revised to include the following: modiﬁed New York Heart Association functional
class I or II, 6-min walk distance 380 to 440 m, cardiopulmonary exercise test–measured peak oxygen
consumption >15 ml/min/kg and ventilatory equivalent for carbon dioxide <45 l/min/l/min, BNP level toward
“normal,” echocardiograph and/or cardiac magnetic resonance imaging demonstrating normal/near-normal
right ventricular size and function, and hemodynamics showing normalization of right ventricular function with right
atrial pressure <8 mm Hg and cardiac index >2.5 to 3.0 l/min/m2. (J Am Coll Cardiol 2013;62:D73–81)
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Abbreviations
and Acronyms
BNP = B-type natriuretic
peptide
CHD-PAH = pulmonary
arterial hypertension related
to congenital heart disease
CI = cardiac index
CMR = cardiac magnetic
resonance
EqCO2 = ventilatory
equivalent for carbon dioxide
FC = functional class
HIV-PAH = pulmonary arterial
hypertension related to
human immunodeﬁciency
virus infection
IPAH = idiopathic pulmonary
arterial hypertension
NIH = National Institutes of
Health
NT-proBNP = N-terminal
pro–B-type natriuretic
peptide
NYHA = New York Heart
Association
PAH = pulmonary arterial
hypertension
PAP = pulmonary artery
pressure
PH = pulmonary
hypertension
PoPH = pulmonary arterial
hypertension related to
portal hypertension
6MWD = 6-min walk
distance
RAP = right atrial pressure
RV = right ventricular
RVEDVI = right ventricular
end-diastolic volume index
SSc-PAH = pulmonary
arterial hypertension related
to scleroderma
SLE-PAH = pulmonary
arterial hypertension related
to systemic lupus
erythematosus
SvO2 = mixed venous
oxygenation
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D74prognostic predictors has been
a key goal for clinicians involved in
the care of patients with pulmo-
nary hypertension (PH). The
National Institutes of Health
(NIH) registry was the ﬁrst to
show the impact of baseline
hemodynamic parameters on out-
come, demonstrating that factors
which govern right heart function
can also determine the prognosis
in patients with PAH (1). Uti-
lizing these parameters, a survival
equation was derived that was
the ﬁrst attempt to use baseline
hemodynamic factors to predict
outcome. The formula included
measurements of right atrial pres-
sure (RAP), cardiac index (CI),
and mean pulmonary artery pres-
sure (PAP), each of which was
shown to contribute indepen-
dently toward the prediction of
risk of death.
With the advent of multiple
clinical trials and the success of
demonstrating better outcome
through improvements achieved
in exercise parameters, the utility
of noninvasive prognostic markers
as surrogates for hemodynamic
indices has been explored. In
particular, the ﬁnding that the
6-min walk distance (6MWD)
test correlated with hemodyna-
mics established its role as a new
baseline prognostic marker and as
a treatment goal. Subsequently, a
growing number of publications
have identiﬁed other prognostic
factors in patients with PAH,
which include assessment of func-
tional class (FC), parameters of
exercise tolerance, hemodynamics,
echocardiographic parameters, and
biomarkers. However, investiga-
tors have recently begun to analyze
the utility of these markers as
prognostic indicators with theavailability of long-term data, in particular the 6MWD. It
is becoming clear that no single parameter can fulﬁll the role
of a reliable prognostic indicator. Composite treatment goals
have been shown to have more meaningful correlation with
outcome, both as baseline predictors and as treatment targets (2).
More recently, 2 large registries have shed light on the
prognosis of patients with PAH in the current therapeuticarea. The French Registry characterized survival and im-
portant prognostic indicators in patients with idiopathic,
familial, and anorexigen-induced PAH. The registry
demonstrated that the survival of this cohort of PAH
patients has improved compared with the predicted
survival on the basis of the NIH registry, although it is
still suboptimal, with 1-, 2-, and 3-year survival of 85.7%,
69.5%, and 54.9%, respectively, for incident cases (3).
Important predictors of survival included sex, FC, exercise
tolerance as measured by using the 6MWD, and hemo-
dynamics, speciﬁcally RAP and cardiac output. Similarly,
in the large, U.S.-based REVEAL (Registry to Evaluate
Early and Long-Term Pulmonary Arterial Hypertension
Disease Management) registry, key predictors of outcome
included etiology of PAH, FC, sex, exercise tolerance,
and hemodynamics that reﬂect right ventricular (RV)
function (4).
Modiﬁed New York Heart Association
Functional Class
Baseline FC is an important correlate and predictor of
survival. This assertion has been found in single-center
cohorts from many countries, the ﬁrst U.S. NIH registry of
idiopathic pulmonary arterial hypertension (IPAH) patients,
and, most recently, conﬁrmed in the REVEAL registry,
which enrolled 2,716 PAH patients of all subtypes (4). It
should be recognized that some studies have found no
association between FC and survival, and in other studies,
FC was found to correlate with survival in univariate analyses,
but this association was lost in multivariate analyses (1,5–8).
During the follow-up assessment of treated PAH
patients, repeated assessment of FC provides important
information regarding the severity of PAH and the response
to therapy, as well as the prognosis for survival. After
institution of effective PAH therapy, clinical improvement
from initial FC III/IV to FC II is associated with improved
prognosis.
There are limitations to the clinical use of modiﬁed New
York Heart Association (NYHA) FC, including poor
interobserver reliability and effects of demographic charac-
teristics (e.g., age, sex, ethnicity) (9). Nevertheless, modiﬁed
NYHA FC is a simple, reproducible, and clinically impor-
tant assessment tool and prognostic measure in PAH
patients, both at the time of diagnosis and at follow-up
during PAH treatment.
6-Min Walk Distance Test
The 6MWD is a simple, noninvasive test that is inex-
pensive, reproducible, and well tolerated in patients
with PAH. Initial studies have shown signiﬁcant correla-
tions between the baseline 6MWD and hemodynamic
parameters, as well as survival (10). Furthermore, the
6MWD has been used as the primary endpoint for almost
all pivotal clinical trials of PAH treatments, and it is
Table 1
Variables Used in Clinical Practice to Determine
Response to Therapy and Prognosis in Patients
With PAH
Functional class
I or II
Echocardiography/CMR
Normal/near-normal RV size and function
Hemodynamics
Normalization of RV function (RAP <8 mm Hg and CI >2.5 to 3.0 l/min/m2)
6-min walk distance
>380 to 440 m; may not be aggressive enough in young individuals
Cardiopulmonary exercise testing
Peak VO2 >15 ml/min/kg and EqCO2 <45 l/min/l/min
B-type natriuretic peptide level
Normal
CI ¼ cardiac index; CMR ¼ cardiac magnetic resonance; EqCO2 ¼ ventilatory equivalent for carbon
dioxide; PAH ¼ pulmonary arterial hypertension; RAP ¼ right atrial pressure; RV ¼ right ventricular;
VO2 ¼ peak oxygen consumption.
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endpoint because it has been shown to serve as a useful
marker of treatment outcome during the pre-deﬁned trial
durations (11).
The 6MWD is widely used by clinicians as an integral
component for assessing prognosis at baseline and treat-
ment effect at follow-up. However, there are many
limitations to 6MWD, including the learning effect, day-
to-day variation, and impact of demographic characteris-
tics and comorbidities. A meta-analysis recently reported
on the usefulness of 6MWD in determining outcome in
PAH. Savarese et al. (12) evaluated the results in 3,112
patients from 22 clinical trials, and they concluded that
pharmacological treatments resulted in signiﬁcant reduc-
tion of all-cause death, hospitalization for PAH, trans-
plant, initiation of rescue therapy, and composite outcome,
but the favorable effects on clinical events were not pre-
dicted by changes in 6MWD.
The other weakness of 6MWD relates to the difﬁculty
in assessing what is a true meaningful difference in walk
distance, beyond achieving statistical signiﬁcance. An
example of this is the “ceiling effect,” which refers to the lack
of sensitivity to detect changes with treatment in patients
with early stage PAH and relatively high 6MWD at base-
line. A similar limitation is shown by the inability to detect
meaningful changes in 6MWD with the use of combination
treatment as add-on therapy (13–15). Gabler et al. (16)
investigated whether changes in 6MWD in the 12-week
treatment period correlated with clinical events. The
authors reported ﬁndings from the pooled analysis that the
change in 6MWD accounted for only 22.1% of the treat-
ment effect; the average difference in 6MWD across the
trials was 22.4 m, and the signiﬁcant threshold effect was
calculated to be 41.8 m. Thus, the study concluded that the
change in 6MWD does not explain a large proportion of the
treatment effect and that, as a surrogate endpoint for clinical
events, it can claim only a modest validity. Mathai et al. (17)performed a study to determine the minimal important
difference from analyzing the 6MWD results of the tadalaﬁl
clinical trial. From their analysis using both distributional
and anchor-based methods, the estimated minimal impor-
tant difference in the 6MWD for PAH patients is
approximately 33 meters. The results of the 2 studies suggest
that the differences in the 6MWD seen in the recent
combination trials may not indicate clinically meaningful
changes.
There remain several relevant important questions in
using 6MWD. These questions include which distance
best correlates with exercise capacity and right heart
function, and whether this should be measured as an
absolute value of 6MWD that is associated with improved
survival in PAH (e.g., >380 m, as suggested from Sitbon
et al. [18], or >440 m, as shown by the REVEAL
registry [4]). Also, should the distance be assessed based
on percent predicted according to patient parameters (i.e.,
age, sex, height) (19)? Another question that remains to
be answered is how improvement(s) in distance translate
into meaningful change in quality of life or survival.
There is evidence to suggest that incorporating other
measurements obtained during the test, such as heart rate
recovery time, may enhance the usefulness in interpreting
6MWD (20).
The current treatment goal for 6MWD is >380 m.
However, we propose to increase this to 380 to 440 m; for
some patients, using percent predicted may better reﬂect an
appropriate goal of therapy.
Cardiopulmonary Exercise Testing
Cardiopulmonary exercise testing provides an integrative
approach to assessing cardiac function, gas exchange, and
muscular physiology. Peak oxygen consumption has been
shown to be predictive of survival in PH, with 3 studies
providing cutoff values of 10.4 ml/min/kg (21), 11.5 ml/
min/kg (22), and 13.2 (23) ml/min/kg below which
mortality is increased, as well as being established as
a prognostic marker in other conditions, such as heart
failure (24).
The development of a right-to-left shunt on exercise has
been shown to be signiﬁcantly and strongly associated with
worse survival; in patients without a shunt, in FC III/IV,
ventilatory equivalent for carbon dioxide (EqCO2) at an
anaerobic threshold <40 l/min/l/min was associated with
excellent survival (25).
Peak oxygen consumption has been suggested as a goal
of therapy, with <10 ml/min/kg indicating poor prognosis
and a need to escalate treatment and with >15 ml/min/kg
indicating better prognosis. In young patients, this may
be a limited approach, and percent predicted peak oxygen
consumption may provide a better indication in this
group (26); this theory requires further evaluation. EqCO2
is less age-dependent, and values <45 l/min/l/min and
>55 l/min/l/min would seem appropriate goals/warning
Table 2
Variables Used in Clinical Practice to Determine
Response to Therapy and Prognosis in Patients With
Pulmonary Arterial Hypertension
Prognostic
Implications
at Baseline
(Ref. #)
Prognostic
Implications
at Follow-Up
(Ref. #) Comments
Exercise tolerance
NYHA FC (2,4,9,10) (2,9,10)
6MWD (2–4,10,61)
Peak VO2 (24)
Hemodynamics
RAP (2,9,10,24,40,50,61,62) (9) In some
studies,
higher
PAPm was
associated
with better
survival
(10,63)
PAPm (1,4)
PVR (24) (9)
CO/CI (2,3,9,24,40,50,61) (2,9)
SvO2 (2,24,64) (2,64)
Echocardiographic
variables
TAPSE (40)
RV strain (65)
RA area (40)
Pericardial
effusion
(4,40)
Biomarkers
BNP/NT-proBNP (2,4,5,62) (2,5,66)
Troponin (62)
Uric acid (24,67,68)
CRP (69)
PaCO2 (61) (61)
MRI parameters
SV index (8)
RVEDVI (8)
LVEDV (8)
RVEF (44) (44)
RVAC (70)
BNP ¼ B-type natriuretic peptide; CI ¼ cardiac index; CO ¼ cardiac output; CRP ¼ C-reactive
protein; LVEDV ¼ left ventricular end-diastolic volume; MRI ¼ magnetic resonance imaging; NYHA
FC ¼ New York Heart Association functional class; NT-proBNP ¼ N-terminal pro–B-type natriuretic
peptide; 6MWD ¼ 6-min walk distance; PaCO2 ¼ partial arterial pressure of carbon dioxide;
PAPm ¼mean pulmonary artery pressure; PVR ¼ pulmonary vascular resistance; RA ¼ right atrial;
RAP ¼ right atrial pressure; RVEDVI ¼ right ventricular end-diastolic volume index; RVEF ¼ right
ventricular ejection fraction; RVFAC ¼ right ventricular fractional area change; SV ¼ stroke volume;
SvO2 ¼mixed venous oxygen saturation; TAPSE ¼ tricuspid annular plane systolic excursion; VO2 ¼
oxygen consumption.
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D76signs for evaluation of the exercise response in relation to
treatment and prognosis. The presence of a right-to-left
shunt opening on exercise should be regarded as an
ominous sign.
Biomarkers
Research on biomarkers has tremendously increased the
understanding of different pathophysiological processes of
PAH, including pulmonary vascular disease (e.g., endothe-
lial dysfunction, in situ thrombosis, oxidative stress), RV
dysfunction, and end-organ failure (e.g., renal failure).
However, only a small minority of the investigated para-
meters have been shown to be clinically relevant. Therelevance of B-type natriuretic peptide (BNP) has been
demonstrated in outcome studies and as a secondary
endpoint in some PAH treatment trials.
Current guidelines suggest a “normal” BNP level as
a potential treatment goal. Therefore, it has to be taken into
account that both BNP and N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) are age- and sex-dependent,
leading to higher normal values (especially with age). Indi-
vidual normal values are given by the manufacturer. An
attempt to individualize BNP values has been suggested by
dividing the measured BNP values by the age- and sex-
speciﬁc normal values. This BNP ratio would be increased
whenever >1 (27,28).
BNP levels have been shown to parallel hemodynamic
and functional responses to PAH therapies in most clinical
trials. Recent data support the hypothesis that the change
in NT-proBNP levels carries prognostic information.
Independently of baseline values, follow-up NT-proBNP
levels <1,800 pg/ml indicated better survival in a cohort
of 84 PAH patients in the current treatment era (2).
An open question remains the position of BNP in the
rank order of various therapy goals. When the goal-oriented
therapy approach was initially proposed for IPAH, natri-
uretic peptides (as many others) were not included as
therapy goals (29). However, because RV failure is the main
cause of death in IPAH, it seems reasonable to have an
observer- and effort-independent, broadly available para-
meter of RV dysfunction as a main therapeutic goal. An
attempt could be made when treatment of PAH is initiated
to reach the “lowest possible” or “personal best” BNP and/or
NT-proBNP. Comparable attempts have been made in
congestive heart failure. In this context, a meta-analysis
found that usage of cardiac peptides to guide pharmaco-
logical therapy signiﬁcantly reduced mortality and heart
failure–related hospitalization in patients with chronic heart
failure (30). There is no evidence that such an approach
would work in PAH, however, and it is questionable if
a study size comparable to that used in congestive heart
failure could be achieved in this rare condition. However, as
mentioned, on the basis of the parallel development of
hemodynamics and BNP/NT-proBNP levels (31) and the
prognostic value of the change and follow-up values
of BNP/NT-proBNP levels (2,5), as well as on the expe-
rience from other disease states, this approach has some
justiﬁcation.
Echocardiography
Echocardiography is widely used as an initial diagnostic
test to conﬁrm the presence of PH and/or RV abnormal-
ities in patients suspected clinically to have PH. However,
its use as a tool to provide prognostic information is based
on a relatively small amount of data, speciﬁcally regarding
echocardiographic assessments of RV function, which is
the key determinant of outcome. The Tei index, although
it has been shown to be predictive of outcome, is not as
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degree of tricuspid regurgitation (32). The other parameter
of RV function that reportedly correlates with survival is
measurement of tricuspid annular plane systolic excursion,
recently shown to be predictive of survival in patients with
PAH-associated scleroderma; these ﬁndings need further
study for conﬁrmation (33,34). Right atrial and ventricular
enlargement and the eccentricity index have also been
shown to correlate with outcome among patients with
IPAH (6). The right atrial area at baseline seems to be 1
of the most robust echocardiographic determinants of
outcome, but it is unclear whether this variable is also
useful for guiding treatment decisions during follow-up
(6,35). Furthermore, presence of a pericardial effusion to
any extent has been shown to be a strong predictor of
mortality (36).
The major limitations in using echocardiographic
parameters for prognostic assessments, especially as a follow-
up marker to guide treatment, relate to the lack of consistent
method of reporting the RV size and function and the
technical difﬁculties in obtaining reproducible right-sided
chamber measurements. There is also variability stemming
from differing skill levels of the technician performing
the test. Furthermore, there is no consensus deﬁning the
severity of PH as assessed by echocardiographic estimates
of RV systolic pressure that correlates with right heart
catheterization–derived parameters.
We recommend maintaining the current recommenda-
tions regarding echocardiographic goals of treatment,
speciﬁcally normal/near-normal RV size and function. The
need to further deﬁne and conﬁrm reliable quantitative
measurements that can be measured, which reﬂect RV
function (i.e., tricuspid annular plane systolic excursion, RA
size) require further study.
Cardiac Magnetic Resonance
Cardiac magnetic resonance (CMR) is the gold standard for
the investigation of right heart structure and volumes (37).
Given that right heart function is accepted as the main
determinant of survival in PAH, this modality would be
expected to provide reliable information regarding prog-
nosis; however, few studies are available that have assessed
this variable’s role in predicting survival (8,38,39). In
response to chronic PH, the right ventricle hypertrophies
and dilates with reducing function and stroke volume. The
interventricular septum bows in to the left ventricle in
diastole and systole. Commensurate with this action, right
ventricular end-diastolic volume index (RVEDVI)<84ml/m2,
left ventricular end-diastolic volume index >40 ml/m2, and
a stroke volume index >25 ml/m2 are associated with better
survival in patients with IPAH (8). RVEDVI was
also shown to be an independent predictor of mortality
by another group of researchers, but the number of events
was too small to generate a threshold value for worse sur-
vival (39). However, according to the study by vanWolferen et al., there were no deaths in patients with
RVEDVI<84ml/m2. Furthermore,RVmass index<59g/m2
showed a trend toward better survival in IPAH, and in
a cohort of patients with suspected scleroderma PAH, the
ratio of RV to left ventricular end-diastolic mass >0.7
predicted worse survival (40). Ejection fraction has also
been assessed and a value <35% shown to be predictive of
mortality (38). Importantly, even in patients with falling
pulmonary vascular resistance, a decrease in ejection fraction
was signiﬁcantly associated with worse prognosis. Pulmo-
nary artery stiffness increases afterload on the right ventricle
and, when measured by using the relative pulmonary artery
area change throughout the cardiac cycle, has also been
associated with increased mortality (41,42).
Although CMR seems to hold promise for evaluation and
follow-up of patients with PH, data are currently limited. It
is not in widespread use for serial follow-up of patients with
PH, and its main role currently resides in baseline diagnosis.
It should not be assumed that myocardial indices are
conserved across the different PH classiﬁcations, and further
evaluation is required before it is considered part of routine
clinical use.
Hemodynamic Parameters
Hemodynamic parameters are considered to be the gold
standard indices of outcome in PAH. The NIH registry
demonstrated that increased mean PAP, increased mean
RAP, and decreased CI were associated with an increased
mortality (1). Since then, hemodynamics (speciﬁcally, RA
pressure, CI, and mixed-venous oxygen saturation [SvO2]
but not mean PAP) have been conﬁrmed in numerous
studies as robust independent prognostic factors (4,43,44).
However, there are several caveats and limitations in using
hemodynamic parameters to assess prognosis. First, as PAH
progresses and the right ventricle dilates and fails, the mean
PAP declines, which is why survival estimates use mean
RAP and CI in the equations. Obtaining hemodynamic
measurements require an invasive procedure that is not
widely available, and the associated risks, albeit small in
experienced centers, limit the ability to obtain follow-up or
serial hemodynamic parameters on treatment. Hemody-
namic measurements also illustrate the physiological state at
a single time point at rest, in a supine position, which does
not account for changes associated with activity. Although
exercise-related hemodynamic effects are currently under-
going active research, there is no consensus regarding the
method of performing exercise right heart catheterization or
interpretation of the hemodynamic effects of exercise in
PAH. Furthermore, the effects of systemic processes such as
anxiety, hypertension, and sedation can markedly affect the
parameters.
The current recommendation advises normalization
of RV function for treatment goal, which is deﬁned as
RAP <8 mm Hg and CI >2.5 l/min/m2. There is a
proposal to increase the CI to >3.0 l/min/m2, and the
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strong evidence for the current recommendation of CI >2.5
l/min/m2 as a hemodynamic goal; it was derived mainly
from studies evaluating patients with left heart failure. The
deﬁnition of normal CI for healthy subjects varies widely
in the literature, from 2.4 to 4.2 l/min/m2, depending on
the sources cited (44–47). There are no direct data from
PAH patients to guide this recommendation. The opinions
in favor of this measure are based on the fact that we need to
establish more ambitious goals in PAH, with clear manda-
tes to “raise the bar” with the common goal of improving
outcome. Clearly, there are patients who have improved
symptoms and exercise capacity with treatments that result
from an increase in cardiac outputs. Thus, given the lack of
evidence supporting 2.5 l/min/m2 as the best goal, the
question is whether to increase the recommended CI to 3.0
l/min/m2. The concerns raised from the panel members
regarding this change include that there is no evidence
that just raising the CI limit translates into better outcome,
and that some physicians may feel compelled to augment
treatments and/or increase doses just to reach the 3.0 l/min/
m2 target, with more risk to patients. Furthermore, from
a physiological standpoint, there is a potential to increase
the workload of the right ventricle in inappropriate settings
and the possibility of incurring damaging effects to the RV
myocardium from detrimental effects of increased cate-
cholamine release.
Given the lack of data regarding the optimal CI in the
PAH population, there seems to be support to recommend
that the target CI as a hemodynamic treatment goal be
adjusted for the individual patient to >2.5 to 3.0 l/min/m2.
The CI is just 1 measure in the evaluation process, however,
and it must be interpreted in the context of all other
hemodynamic variables as well as clinical parameters.
Current Status of Prognostic Predictors in PAH
Recently, Nickel et al. (2) reported a systemic evaluation of
prognostic markers at baseline and follow-up in a series of
patients with IPAH. They identiﬁed 4 variables that were
independently associated with survival at baseline as well
as at follow-up: NYHA FC, NT-proBNP, CI, and
SvO2. NYHA FC I and II, NT-proBNP <1,800 ng/l,
CI 2.5l/min/m2, and SvO2 65% during follow-up were
associated with a better survival. Of note, the follow-up
assessments were found to be better outcome predictors
than the baseline evaluations; in fact, the outcome was
almost entirely determined by the variables obtained at
follow-up rather than by using the baseline measurements.
Thus, both baseline and follow-up assessments are im-
portant when assessing the risk of patients with PAH. The
baseline evaluation will determine disease severity at
presentation, providing important information for choosing
the initial therapy. Follow-up assessments are crucial for
assessing the response to treatment, and they seem to
provide a more reliable prognostic estimation than thebaseline evaluation. Table 1 summaries the variables used in
clinical practice to determine response to therapy and
progress in patients with PAH.
Notably, use of 1 parameter is not sufﬁcient to reﬂect the
status of RV function; multiple variables must be inter-
preted in the context of each individual patient. A proposal
to rank the parameters has been suggested, with prioriti-
zation of markers (i.e., objective parameters such as
hemodynamics ranked ﬁrst/highest or categorize variables
into major versus minor criteria); this proposal warrants
further consideration, but current data are insufﬁcient to
validate such a ranking system. Table 2 reviews the clinical
observations on speciﬁc variables.
Risk scores and prognostic equations have served as
useful predictors of survival on a population basis, but
currently, none has been adequately studied or validated as
a goal of therapy. How an individual’s change in score
reﬂects that individual’s subsequent prognosis has not yet
been adequately studied. In addition, some risk scores
(e.g., REVEAL) include a number of variables that cannot
change, even when the response to therapy is favorable
(i.e., age, sex, etiology). We advocate for a multiparameter
approach to treatment goals and hope that data from large
registries may aide in developing a scoring system that
can be used to assess response to therapy, and to establish
goals of therapy using the modiﬁable parameters as
variables.
Are Treatment Goals Different in
Different PAH Subgroups?
PAH is a heterogeneous group of diseases with numerous
subgroups deﬁned according to associated or causative
conditions. Common examples include PAH related to
connective tissue disease, including PAH related to sclero-
derma (SSc-PAH) and systemic lupus erythematosus
(SLE-PAH); PAH related to congenital heart disease
(CHD-PAH); PAH related to human immunodeﬁciency
virus infection (HIV-PAH); and PAH related to portal
hypertension (PoPH). It is relevant to ask whether treat-
ment goals should differ for these various subgroups.
The paucity of published data addressing this question
makes it impossible to provide clear answers in most cases.
Although the prognosis for patients with SSc-PAH
remains poor, it has improved, as shown in recent reports
(48–50). The current treatment goals for patients with SSc-
PAH are not well deﬁned and are generally similar to those
used in other types of PAH. However, functional goals (e.g.,
FC, 6MWD) and biomarkers (e.g., BNP) may be unreliable
in SSc-PAH because of the systemic nature of scleroderma
(51,52). Given the poor prognosis in SSc-PAH, it is
important to explore whether more aggressive treatment
goals will result in improved outcomes in the future. Out-
comes for patients with SLE-PAH seem to be better than
those for SSc-PAH patients (48). Intensive immunosup-
pression may enhance the beneﬁt of PAH-speciﬁc
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optimal treatment of inﬂammation can be considered a
unique treatment goal in SLE-PAH.
Patients with CHD-PAH have a better prognosis than
other subgroups (54), and bosentan was shown to be safe
and effective in a study performed speciﬁcally in this pop-
ulation (55). Patients with HIV-PAH have a worse prog-
nosis than other subgroups, although outcomes have
improved (56). There are no data currently to suggest that
treatment goals in CHD-PAH or HIV-PAH should differ
from those in other PAH subgroups.
Patients with PoPH have a worse prognosis than other
subgroups of PAH (57), although more favorable outcomes
have been reported (58), likely related to less severe liver
disease in this cohort. Treatment goals in selected patients
with PoPH may focus more on invasive hemodynamics
because the achievement of speciﬁc PAP and pulmonary
vascular resistance goals can allow for successful liver
transplantation (59).
There are few data to suggest that treatment goals should
differ for different PAH subgroups. Exceptions include the
limited utility of functional and biomarker goals in SSc-
PAH and the primacy of hemodynamic goals in patients
with PoPH being considered for liver transplantation.
Conclusions
Although the primarily observational studies discussed here
do not allow for deﬁnitive conclusions, reasonable goals of
therapy include the following: 1) modiﬁed NYHA FC I or
II; 2) echocardiography/CMR of normal/near-normal RV
size and function; 3) hemodynamic parameters showing
normalization of RV function (RAP <8 mm Hg and CI
>2.5 to 3.0 l/min/m2); 4) 6MWD of >380 to 440 m
(which may not be aggressive enough); 5) cardiopulmonary
exercise testing, including peak oxygen consumption >15
ml/min/kg and EqCO2 <45 l/min/l/min; and 6) normal
BNP levels.
Patients who achieve these goals, no matter which
speciﬁc therapy or approach is used, seem to have a better
prognosis than those who do not. A more aggressive
approach to goal-oriented therapy may help us shift the
survival curves farther to the right. Despite the many
observations that support attainment of such goals, many
patients followed up today fall far short of these targets.
For example, approximately 60% of FC III patients and
50% of FC IV patients in the REVEAL registry are not
being treated with a prostacyclin, despite their not being
at the goal FC level of I or II (60). Both patient and phy-
sician reluctance to proceed to the most aggressive therapy
are contributing factors.
Survival in PAH has improved over recent years, but
outcomes are still suboptimal. Reasonable therapeutic goals
that primarily reﬂect RV function have been established.
Achieving such goals with optimal application of our current
therapies and further development of novel therapies mayimprove long-term outcomes in patients with this previously
fatal disease.
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